BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 21314941)

  • 1. Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma.
    Carén H; Djos A; Nethander M; Sjöberg RM; Kogner P; Enström C; Nilsson S; Martinsson T
    BMC Cancer; 2011 Feb; 11():66. PubMed ID: 21314941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists.
    Mossman D; Kim KT; Scott RJ
    BMC Cancer; 2010 Jul; 10():366. PubMed ID: 20618997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma.
    Alaminos M; Dávalos V; Ropero S; Setién F; Paz MF; Herranz M; Fraga MF; Mora J; Cheung NK; Gerald WL; Esteller M
    Cancer Res; 2005 Apr; 65(7):2565-71. PubMed ID: 15805250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers.
    Decock A; Ongenaert M; Hoebeeck J; De Preter K; Van Peer G; Van Criekinge W; Ladenstein R; Schulte JH; Noguera R; Stallings RL; Van Damme A; Laureys G; Vermeulen J; Van Maerken T; Speleman F; Vandesompele J
    Genome Biol; 2012 Oct; 13(10):R95. PubMed ID: 23034519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma tumors.
    Olsson M; Beck S; Kogner P; Martinsson T; Carén H
    Epigenetics; 2016; 11(1):74-84. PubMed ID: 26786290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide DNA methylation analysis identifies MEGF10 as a novel epigenetically repressed candidate tumor suppressor gene in neuroblastoma.
    Charlet J; Tomari A; Dallosso AR; Szemes M; Kaselova M; Curry TJ; Almutairi B; Etchevers HC; McConville C; Malik KT; Brown KW
    Mol Carcinog; 2017 Apr; 56(4):1290-1301. PubMed ID: 27862318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas.
    Fujita T; Igarashi J; Okawa ER; Gotoh T; Manne J; Kolla V; Kim J; Zhao H; Pawel BR; London WB; Maris JM; White PS; Brodeur GM
    J Natl Cancer Inst; 2008 Jul; 100(13):940-9. PubMed ID: 18577749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression.
    Vallot C; Stransky N; Bernard-Pierrot I; Hérault A; Zucman-Rossi J; Chapeaublanc E; Vordos D; Laplanche A; Benhamou S; Lebret T; Southgate J; Allory Y; Radvanyi F
    J Natl Cancer Inst; 2011 Jan; 103(1):47-60. PubMed ID: 21173382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma.
    Foltz G; Ryu GY; Yoon JG; Nelson T; Fahey J; Frakes A; Lee H; Field L; Zander K; Sibenaller Z; Ryken TC; Vibhakar R; Hood L; Madan A
    Cancer Res; 2006 Jul; 66(13):6665-74. PubMed ID: 16818640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma.
    Wong CM; Ng YL; Lee JM; Wong CC; Cheung OF; Chan CY; Tung EK; Ching YP; Ng IO
    Hepatology; 2007 May; 45(5):1129-38. PubMed ID: 17464989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methylation fingerprint of neuroblastoma reveals new biological and clinical insights.
    Gómez S; Castellano G; Mayol G; Suñol M; Queiros A; Bibikova M; Nazor KL; Loring JF; Lemos I; Rodríguez E; de Torres C; Mora J; Martín-Subero JI; Lavarino C
    Epigenomics; 2015 Oct; 7(7):1137-53. PubMed ID: 26067621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.
    Heller G; Schmidt WM; Ziegler B; Holzer S; Müllauer L; Bilban M; Zielinski CC; Drach J; Zöchbauer-Müller S
    Cancer Res; 2008 Jan; 68(1):44-54. PubMed ID: 18172295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a functional epigenetic approach to identify promoter region methylation in phaeochromocytoma and neuroblastoma.
    Margetts CD; Morris M; Astuti D; Gentle DC; Cascon A; McRonald FE; Catchpoole D; Robledo M; Neumann HP; Latif F; Maher ER
    Endocr Relat Cancer; 2008 Sep; 15(3):777-86. PubMed ID: 18499731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis.
    Sova P; Feng Q; Geiss G; Wood T; Strauss R; Rudolf V; Lieber A; Kiviat N
    Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):114-23. PubMed ID: 16434596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of genes epigenetically silenced by CpG methylation in human gastric carcinoma.
    Jee CD; Kim MA; Jung EJ; Kim J; Kim WH
    Eur J Cancer; 2009 May; 45(7):1282-1293. PubMed ID: 19195878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation.
    Dannenberg LO; Edenberg HJ
    BMC Genomics; 2006 Jul; 7():181. PubMed ID: 16854234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative epigenomics of human and mouse mammary tumors.
    Demircan B; Dyer LM; Gerace M; Lobenhofer EK; Robertson KD; Brown KD
    Genes Chromosomes Cancer; 2009 Jan; 48(1):83-97. PubMed ID: 18836996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells.
    Zhang C; Li H; Zhou G; Zhang Q; Zhang T; Li J; Zhang J; Hou J; Liew CT; Yin D
    J Pathol; 2007 Jun; 212(2):134-42. PubMed ID: 17471463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel target genes by an epigenetic reactivation screen of renal cancer.
    Ibanez de Caceres I; Dulaimi E; Hoffman AM; Al-Saleem T; Uzzo RG; Cairns P
    Cancer Res; 2006 May; 66(10):5021-8. PubMed ID: 16707423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.
    Yang Q; Zage P; Kagan D; Tian Y; Seshadri R; Salwen HR; Liu S; Chlenski A; Cohn SL
    Clin Cancer Res; 2004 Dec; 10(24):8493-500. PubMed ID: 15623630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.